SEC Company Response from KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA) — May 2, 2008

KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: May 2, 2008 · CIK: 0001075880 · Accession: 0000950123-08-005055

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

May 2, 2008

Author

David Seaton

Form

CORRESP

Company

KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)

Letter

Re:

LETTER TO THE SEC

May 2, 2008

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.W.

Washington, D.C. 20549

Novogen Limited

Ladies and Gentlemen:

Novogen Limited (the “Company”) is in receipt of the comment letter, dated April 11, 2008, from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC”) with respect to the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2007 (File No. 0-29962).

The Company will submit its written response to the comments raised by the Staff in the letter to the SEC via EDGAR no later than Friday, May 16, 2008.

NOVOGEN LIMITED

By:

/s/ David Seaton

Name: David Seaton

Title: Chief Financial Officer

Novogen Limited abn 37 063 259 754 140 Wick Road, North Ryde NSW 2113,Australia Telephone +61 2 9878 0088 Facsimile +61 2 9878 0055

nobogen@novogen.com www.novogen.com

Show Raw Text

CORRESP
1
filename1.htm

LETTER TO THE SEC

May 2, 2008

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.W.

Washington, D.C. 20549

    Re:

     Novogen Limited

Ladies and Gentlemen:

          Novogen Limited (the “Company”) is in receipt of the comment letter, dated April 11, 2008,
from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “SEC”) with
respect to the Company’s Annual Report on Form 20-F for the fiscal year ended June 30, 2007
(File No. 0-29962).

          The Company will submit its written response to the comments raised by the Staff in the
letter to the SEC via EDGAR no later than Friday, May 16, 2008.

    NOVOGEN LIMITED

    By:

 /s/ David Seaton

    Name:
    David Seaton

    Title:
    Chief Financial Officer

Novogen Limited abn 37 063 259 754 140 Wick Road, North Ryde NSW 2113,Australia Telephone +61 2 9878 0088 Facsimile +61 2 9878 0055

nobogen@novogen.com www.novogen.com

SecProbe.io